The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Hemodialysis patients with low bone density (total hip T-score <-2.5) will be assigned to receive teriparatide (those with histologic confirmation of adynamic bone disease) or ibandronate (subjects with increased osteoclast number on bone biopsy).

Follow-up period: one year. A second bone biopsy at the end of the study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Papageorgiou General Hospital
• Treatments: Diphosphonates; Ibandronic Acid; Teriparatide

Criteria

Inclusion Criteria:

• Bone mineral density (T-score<-2.5)

• Adynamic bone disease for the teriparatide group

• Increased osteoclast number on bone biopsy (high turnover) for the ibandronate group

• Calcium greater than 8.1 mg/dl

Exclusion Criteria:

• Suspected carcinoma

• Unstable clinical setting